BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
Ajanta Pharma Ltd.’s business model offers a distinct mix of consistency and fast growth with strong operating metrics (debt-free balance sheet, return on equity more than 20%).
The company derives 68% of its revenues from the branded generic markets of India, Africa and Asia, which lend long term earnings visibility, while its U.S. business is scaling up fast, driving operating leverage benefits.
The culmination of a large capex (Rs 13 billion over FY17-21) should further aid Ajanta Pharma's growth and drive a 21% earnings per share compound annual growth rate over FY20-23E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR